ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintTitle ChevronIcon Twitter
Coronavirus

Japan approval for remdesivir expected 'soon,' Abe says

Antiviral drug will receive fast-track status if certified by another nation

Prime Minister Shinzo Abe speaks in the Diet parliamentary building in Tokyo on April 27. (Photo by Uichiro Kasai)

TOKYO -- Japan is on the verge of initiating a fast-track approval process for Gilead Sciences' antiviral drug remdesivir to treat patients infected by the novel coronavirus, Prime Minister Shinzo Abe said Monday.

Japan's health ministry will place remdesivir on a shortened authorization track once another nation certifies the drug to treat COVID-19. Results from international clinical trials are expected shortly.

Abe told legislators in parliament he expected the drug to qualify for approval "soon." That would make remdesivir the first treatment approved in Japan for COVID-19, the disease caused by the new coronavirus.

Remdesivir was developed by U.S. drugmaker Gilead as a candidate to treat Ebola. The drug reportedly carries the risk of side effects, such as impaired kidney function.

Approval by the health ministry is required for making the treatment available under Japan's national health insurance program.

The prime minister also touted efforts to approve Avigan, an influenza drug developed by Japan's Fujifilm Holdings, as another treatment option for the coronavirus.

"We are doing all we can to expand use on patients who so choose and enable early approval," Abe said.

Avigan "has already been administered in over 2,000 cases, and we have received reports of its effectiveness in relieving symptoms," he added.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends January 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more